Sequenta Issued Third U.S. Patent, Augmenting Its Strong Intellectual Property Portfolio
Patent Covering Clonal Evolution Solidifies Sequenta's Position as Leader in the Field of Minimal Residual Disease (MRD) Testing for Blood Cancers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta Inc. today announced the issuance of its third U.S. patent, “Monitoring Health and Disease Status Using Clonotype Profiles” (Patent No. 8,628,927), which covers minimal residual disease (MRD) monitoring under conditions of clonal evolution, a common source of false negative results with existing MRD detection technology. The methods covered by this patent will provide exclusive protection for Sequenta’s ClonoSIGHT™ test in a range of cancers where clonal evolution commonly occurs, such as leukemias and non-Hodgkin’s lymphoma. Sequenta has now been issued a total of nine patents worldwide and has pending allowances in an additional three U.S. applications.
“We are the only entity that we know of with issued or allowed patents covering the use of next-generation sequencing for MRD detection in lymphoid cancers.”
“Sequenta is committed to bringing ultra-sensitive minimal residual disease detection to all patients with lymphoid cancers through our ClonoSIGHT test,” said Tom Willis, CEO of Sequenta. “We are the only entity that we know of with issued or allowed patents covering the use of next-generation sequencing for MRD detection in lymphoid cancers.”
Sequenta’s other U.S. patents cover sequencing-based MRD monitoring and single-cell analysis of lymphocytes. Additionally, in 2013, Sequenta gained exclusive rights to iRepetoire’s early intellectual property on novel sequencing-based methods of immune repertoire analysis, which complements Sequenta’s MRD intellectual property.
“Our early investments in immune repertoire sequencing technology and the intellectual property surrounding this revolutionary approach to immune profiling have positioned Sequenta as the leader in this space both in terms of our clinical product offerings and the patent protection surrounding them,” said Willis. “These investments will allow us to maintain our leadership in the field of MRD detection as the use of next-generation sequencing becomes a standard of medical care.”
About Minimal Residual Disease
Minimal residual disease (MRD) refers to cancer cells that may remain in the body of a person with lymphoid cancer after treatment. These cells are present at levels undetectable by traditional microscopic examination (also called morphologic examination) of blood, bone marrow or a lymph node biopsy. Very low levels of MRD can be reliably detected only by using sensitive molecular technologies, such as the next-generation sequencing utilized by Sequenta’s ClonoSIGHT test.
About the ClonoSIGHT™ Test
Sequenta’s ClonoSIGHT test enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool for patients with lymphoid cancers (blood cancers). Testing for MRD can help determine whether treatment has been successful, provide important information about patient prognosis and help guide additional treatment decisions. Clinical validation studies have shown that the ClonoSIGHT test, which utilizes Sequenta’s LymphoSIGHT™ platform, offers significant improvements in sensitivity and performance over traditional MRD detection methods.
The ClonoSIGHT test uses a two-step process that is easily integrated into patient care. First, cancer cell DNA sequences are identified in a diagnostic sample. Follow-up samples are then screened for these sequences to detect MRD. ClonoSIGHT test results, which are generated in seven days using Sequenta’s CLIA-certified laboratory, are provided in a simple, actionable report that shows a patient’s MRD status and level, as well as MRD trends over time.
Sequenta is a venture-backed biotechnology company dedicated to improving patient care in diseases mediated by immune cells through the discovery and development of novel clinical diagnostics. The company, located in South San Francisco, was founded in 2008 and has received funding from Mohr Davidow Ventures, Index Ventures and Foresite Capital. For more information, please visit www.sequenta.com.